Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Biosign Develops Algorithm for use in Pre-Screening for Arrhythmia

November 10, 2011

TORONTO, Nov. 10, 2011 /PRNewswire/ – Biosign Technologies Inc. (TSXV: BIO) a company focused on non-invasive monitoring of common health risks associated
with blood pressure, life style and medication, is pleased to announce
they have developed proprietary algorithms that can be utilized on the
UFIT generated pulse waveform as a prescreening tool for arrhythmia.

Biosign has published today “UFIT® Detection of Instantaneous Arrhythmic
and Amplitude Anomalies” a 916 page report available at www.biosign.com/diaa. This report includes an overview of its current work in this field and
in excess of 800 UFIT acquired pulse waveforms that demonstrate UFIT
advanced pulse and anomaly detection algorithms for automatic detection
of arrhythmic events, followed by classification within a domain.

In current practice, the electrocardiogram (ECG) is utilized for the
detection of abnormal electrical activity, which may cause arrhythmic
events, i.e., events in which the normal rhythm of the heartbeat is
interrupted. The detection of these events is important since they can
lead to the deterioration of the mechanical functioning of the heart.
While the ECG may be well suited to detect and classify these events,
it is not nearly as ubiquitous, nor as simple, a measurement as that of
the pulse.

Biosign’s UFIT® acquired pulse waveform, or sphygmogram, is a measure of
the changes in pulse pressure that occurs within the radial artery at
the wrist. Although every electrical contraction of the heart may not
result in a pressure wave that travels through the arterial system,
every pulse detected by the UFIT® is preceded by a ventricular
myocardial contraction. Thus, it follows that irregularities of
heartbeats that do not prevent the ejection of blood into the arteries
are captured in the sphygmogram. Additionally, evidence suggests that
the radial pulse captures arrhythmic events via rate and amplitude
changes within the pulse waveform.

“Our company has a long history of focusing on cardiovascular disease
and developing new solutions to improve lives around the world” said
Dr. Scott Jenkins, Biosign CEO. “With cost effect pre-screening
methodology that will find conditions earlier, we can ensure that the
correct diagnostic tests are given to the patients who need them”.

It is estimated the global cardiovascular disease diagnostics market
will reach $12.4 billion by 2015, based on a report by Global Industry
Analysts, Inc. Biosign sees these new algorithms imbedded into a
standalone application to be utilized as a prescreening test for
arrhythmias, as well as a tool for monitoring changes in arrhythmias
over time.

About Biosign Technologies Inc.

Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems. Key
applications include intelligent systems for noninvasive monitoring of
common health risks associated with blood pressure, glucose, and
medication. The core technology combines measurement, analysis, and
rapid knowledge formation to support health monitoring across global
markets. The UFIT® medical device technology powers quality data
collection and analytics for clinical diagnostics, self-care, wellness,
disease state evaluation & management, and remote patient monitoring.
For more information on Biosign, please visit www.biosign.com

Forward-Looking Statements

This release contains forward-looking statements. Forward-looking
statements, without limitation, may contain the words believes,
expects, anticipates, estimates, intends, plans, or similar
expressions. Forward-looking statements are not guarantees of future
performance. They involve risks, uncertainties and assumptions and
Biosign’s actual results could differ materially from those
anticipated. Forward looking statements are based on the opinions and
estimates of management at the date the statements are made, and are
subject to a variety of risks and uncertainties and other factors that
could cause actual events or results to differ materially from those
projected in the forward-looking statements. In the context of any
forward-looking information please refer to risk factors detailed in,
as well as other information contained in, Biosign’s filings with
Canadian securities regulators (www.sedar.com).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or accuracy
of this release.

 

SOURCE Biosign Technologies Inc.


Source: PR Newswire